NYMOX Updates Shareholders
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) provided an update on its business activities, assuring shareholders that plans are progressing and ongoing initiatives are advancing positively. Dr. Paul Averback, President and CEO, emphasized that the company is well-funded and has made advancements in key projects despite setbacks. Nymox anticipates sharing important updates during the summer and in Q3 and Q4. The company acknowledges the inherent risks and uncertainties in clinical drug development, particularly relating to its primary product, Fexapotide, for treating BPH and prostate cancer.
- Nymox has confirmed ongoing development and progress in its business activities.
- The company is well-funded, allowing it to advance key projects despite previous setbacks.
- The press release highlights uncertainties in clinical drug development and regulatory approval processes.
IRVINE, Calif., July 15, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced an update to its shareholders regarding progress in the Company business activities. Nymox wishes to assure our shareholders that business plans are continuing to be developed and are on track. The Company will provide regular and further specific details when there is upcoming material information available to share. In the meantime, ongoing initiatives are continuing and are being positively advanced.
Dr. Paul Averback, President and CEO stated, "The Company is well funded and despite setbacks we have advanced our main projects. We expect to provide important further details this summer and also this fall in Q3 and Q4."
For more information please contact info@nymox.com or 800-936-9669.
Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2021, and its Quarterly Reports.
For Further Information Contact:
Randall Lanham
1-800-93NYMOX
www.nymox.com
FAQ
What is the latest update from Nymox Pharmaceutical Corporation regarding its business activities?
What projects is Nymox focusing on currently?
When can shareholders expect more information from Nymox?
What risks does Nymox face in its drug development process?
